<DOC>
	<DOCNO>NCT01531361</DOCNO>
	<brief_summary>The goal clinical research study find high tolerable dose combination ZelborafTM ( vemurafenib ) Nexavar® ( sorafenib ) Xalkori® ( crizotinib ) give patient advanced cancer . The safety drug also study . Vemurafenib design block protein call BRAFV600E inside cancer cell , involved cancer cell growth . Sorafenib design block function important protein outside cancer cell . These protein involve cancer cell growth new blood vessel development . Crizotinib design block certain abnormal gene find cancer cell . This may cause cancer cell die .</brief_summary>
	<brief_title>Sorafenib Crizotinib Vemurafenib Advanced Cancer</brief_title>
	<detailed_description>Study Groups : Dose escalation : If find eligible take part study , doctor decide receive vemurafenib either sorafenib crizotinib . Once decided combination receive , assign dose level base join study . Up 6 dose level vemurafenib sorafenib test . Up 5 dose level vemurafenib crizotinib test . Up 6 participant enrol dose level . The first group participant receive low dose level . Each new group receive high dose group , intolerable side effect see . This continue high tolerable dose vemurafenib either sorafenib crizotinib find . Dose expansion : Once high tolerable dose vemurafenib either sorafenib crizotinib find , 14 participant may enrol . This study safety combination drug dose level effectiveness study drug certain tumor group . Study Drug Administration : Each study cycle 28 day . You take vemurafenib mouth 2 time day time every day either without food , swallow whole glass water . Tablets chew crush . If miss dose , take 4 hour next dose . You take dos time . You take sorafenib mouth time every day without food ( least 1 hour 2 hour meal ) . Depending dose level enrol , take sorafenib mouth either 1 2 time day . The doctor discus . You take crizotinib mouth time every day consistently either without food , swallow whole glass water . Depending dose level receiving , take crizotinib mouth either 1 2 time day . The doctor discus . Study Visits : At every study visit , ask side effect . Around Days 1 , 8 , 15 , 22 Cycle 1 Day 1 Cycles 2 beyond : - Blood ( 2-4 tablespoon ) draw mutation/genetic testing . Mutation/genetic test look whether specific gene change ( mutate ) tumor . - Urine collect mutation/genetic testing . You may collect first urine morning , anytime day , may collect urine 24 hour . You give container collect urine tell use . If collect urine 24 hour , study staff give large ( 3-liter ) urine storage container small ( 7-ounce ) plastic collection container . You urinate small collection container pour urine large urine storage container within 10 minute collection . You write time first last collection large storage container return study staff end 24-hour period . If collect first urine morning , study staff give 3 plastic collection cup 3 small tube fill preservative solution . To collect first morning urine , fill collection cup urine 100 mL ( milliliter ) line , add 1 small tube preservative cup within 10 minute , mark container first morning urine . If possible , fill 2 collection cup , add tube preservative describe mark part first morning urine . You return collection cup study staff next visit . If collect urine anytime suit , study staff give 3 plastic collection cup 3 small tube fill preservative solution . To collect urine , fill collection cup urine 100 mL line , add 1 small tube preservative cup within 10 minute , mark container first morning urine . If possible , fill 2 collection cup , add tube preservative describe mark study doctor know time collect urine . You return collection cup study staff next visit . Your study doctor staff give detail , need . Around Days 15-21 Cycle 1 : - Your medical history record , include cancer symptom . - You physical exam , include measurement weight vital sign . - You ask health problem may drug herbal supplement may take . - Your performance status record . - Blood ( 1 tablespoon ) drawn routine test . Before start Cycles 2 beyond : - Your medical history record , include cancer symptom . - You physical exam , include measurement weight vital sign . - You ask health problem may drug herbal supplement may take . - Your performance status record . - Blood ( 1 tablespoon ) drawn routine test . - If able become pregnant , blood ( 1 teaspoon ) urine pregnancy test . Every cycle ( every 8 week ) : - Blood ( 1 tablespoon ) drawn check thyroid gland . - You skin exam skin doctor check lesion might skin cancer . - You x-ray , CT scan , MRI , and/or PET/CT scan check status disease . Blood ( 1 tablespoon ) drawn tumor marker test . After least 6 month take study drug , may CT , MRI , and/or PET/CT scan blood drawn every 3 cycle ( every 12 week ) study doctor think need . If study doctor change dose study drug , blood ( 1 tablespoon ) drawn check abnormal mineral . Anytime study study doctor think need : - You ECG check heart function . - Blood ( 1 tablespoon ) collect abnormal mineral digestive enzyme test . - If take blood thinner warfarin , blood ( 1 teaspoon ) drawn test well blood clot . Length Dosing : You may continue take study drug long doctor think best interest . You longer able take study drug disease get bad , intolerable side effect occur , unable follow study direction . Follow-up : You follow-up-visit within 30 day last dose study drug . The following test procedure perform : - You ask health problem may side effect . - If disease gotten bad , blood ( 2-4 tablespoon ) draw mutation/genetic testing . - If disease gotten bad , urine collect mutation/genetic testing . You may collect first urine morning , anytime day , may collect urine 24 hour . If study doctor think need , may follow-up long period time . You may skin exam within 6 month last dose study drug check new lesion may skin cancer doctor think need . This investigational study . Vemurafenib FDA approve commercially available treat progressive melanoma BRAFV600E mutation . Sorafenib FDA approve commercially available treat progressive hepatocellular carcinoma renal cell carcinoma . Crizotinib FDA approve commercially available treat locally advance metastatic non-small lung cancer . Giving combination vemurafenib either sorafenib crizotinib patient advance cancer investigational . Up 183 patient enrol study . All enrol MD Anderson .</detailed_description>
	<mesh_term>Neoplasms</mesh_term>
	<mesh_term>Sorafenib</mesh_term>
	<mesh_term>Crizotinib</mesh_term>
	<mesh_term>Niacinamide</mesh_term>
	<criteria>1 . Patients advance metastatic cancer BRAF mutation refractory standard therapy , relapse standard therapy , standard therapy available improves survival least three month . Patients BRAF mutation cell free DNA ( test CLIA lab ) also eligible . 2 . Patients must &gt; /= 3 week beyond treatment cytotoxic chemotherapy regimen , therapeutic radiation , major surgery . Patients may receive palliative localize radiation immediately treatment provide radiation deliver site disease treat protocol . For biologic/targeted agent patient must &gt; /= 5 halflives &gt; /= 3 week last dose ( whichever come first ) . Patients previously treat vemurafenib monotherapy stop medication start protocol . 3 . ECOG performance status &lt; /= 2 4 . Patients must &gt; /= 18 year age . 5 . Patients must adequate organ marrow function define : absolute neutrophil count ( ANC ) &gt; /= 1,000/mL , platelet &gt; /=75,000/mL ; creatinine &lt; /= 2 X ULN ; total bilirubin &lt; /= 2 X ULN ( exception may apply benign nonmalignant indirect hyperbilirubinemia Gilbert syndrome ) ; ALT ( SGPT ) and/or AST ( SGOT ) &lt; /= 5 X ULN Exception patient liver metastasis : total bilirubin &lt; /= 3 x ULN ; ALT ( SGPT ) &lt; /= 8 X ULN . 6 . Dermatology evaluation excision suspicious lesion prior initiation therapy . 7 . Women childbearing potential men must agree use adequate contraception ( hormonal barrier method birth control ; abstinence ) prior study entry , duration study participation , 30 day last dose . 8 . Women childbearing potential must negative serum urine pregnancy test within 2 week prior initiation therapy . 9 . Life expectancy &gt; 12 week opinion Investigator . 10 . Patients must able understand willing sign write informed consent document . 11 . Patient must able swallow pill . 1 . Uncontrolled intercurrent illness , include , limited , uncontrolled infection , uncontrolled asthma , need hemodialysis , need ventilatory support . 2 . Syndrome congenital QTc prolongation QTc &gt; 500 msec . 3 . Patients clinically significant cardiovascular disease : history cerebrovascular accident ( CVA ) within 6 month , myocardial infarction unstable angina within 6 month , unstable angina pectoris . 4 . Pregnant lactating woman . 5 . History hypersensitivity vemurafenib . 6 . History hypersensitivity sorafenib vemurafenib/sorafenib arm . 7 . History hypersensitivity crizotinib vemurafenib/crizotinib arm . 8 . History hypersensitivity component formulation . 9 . Patients unwilling unable sign inform consent document . 10 . Patients use follow medication : mesoridazine , dronedarone , thioridazine , ziprasidone , levomethadyl , saquinavir vemurafenib/sorafenib arm .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2017</verification_date>
	<keyword>Advanced Cancers</keyword>
	<keyword>Advanced Malignancies</keyword>
	<keyword>Metastatic cancer</keyword>
	<keyword>Vemurafenib</keyword>
	<keyword>PLX4032</keyword>
	<keyword>R05185426</keyword>
	<keyword>Sorafenib</keyword>
	<keyword>Nexavar</keyword>
	<keyword>Bay 43-9006</keyword>
	<keyword>Crizotinib</keyword>
	<keyword>PF-02341066</keyword>
	<keyword>Xalkori</keyword>
	<keyword>Maximum tolerate dose</keyword>
	<keyword>MTD</keyword>
	<keyword>Dose limit toxicity</keyword>
	<keyword>DLT</keyword>
</DOC>